Orphai Therapeutics Is A Clinical Stage Biopharmaceutical Company Focused On Developing Innovative Therapeutics For Rare Diseases And Cancerfounded In 2013 And Rebranded In September 2023The Company Operates Under The Biotechnology Accelerator 4Catalyzerit Aims To Address Unmet Medical Needs Through Ai Driven Drug Discovery And Clinical Development The Company Utilizes Its Guardian Angela C Platformwhich Employs Deep Learning To Analyze Disease Biology And Identify Therapeutic Candidatesorphai Has Advanced Three Drugs Into Clinical Trialsincluding Ait 101A Pikfyve Kinase Inhibitor Currently In Phase Ii Trials For Alsthe Company Holds 25 Patents And Has A Diversified Pipeline Targeting Rare Pulmonary And Oncologic Indicationsorphai Collaborates With Clinical And Academic Partners To Enhance Its Research And Development Effortsemphasizing A Commitment To Patient Care In The Realm Of Rare Diseases
No conferences found for this company.
| Company Name | Ai Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
